当前位置: X-MOL 学术Br. Med. Bull. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Obeticholic acid-a new therapy in PBC and NASH.
British Medical Bulletin ( IF 7.4 ) Pub Date : 2020-04-13 , DOI: 10.1093/bmb/ldaa006
Roger W Chapman 1, 2 , Kate D Lynch 1, 2, 3, 4
Affiliation  

Obeticholic acid (OCA) is a semi-synthetic hydrophobic bile acid (BA) analogue that is highly selective agonist of farnesoid X receptor (FXR), a key nuclear BA receptor, which induces expression of gut-derived hormones, in particular fibroblast growth factor 19. The resulting beneficial effects of OCA on glucose and lipid metabolism and particularly hepatic inflammation make it a candidate for the treatment of a variety of conditions including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).

中文翻译:

奥贝胆酸-一种在PBC和NASH中的新疗法。

奥贝胆酸(OCA)是一种半合成的疏水胆汁酸(BA)类似物,是法尼醇X受体(FXR)的高度选择性激动剂,该受体是关键的核BA受体,可诱导肠源性激素特别是成纤维细胞生长因子的表达19. OCA对葡萄糖和脂质代谢特别是肝炎症产生的有益作用使其成为治疗多种疾病的候选药物,包括原发性胆源性胆管炎(PBC)和非酒精性脂肪性肝炎(NASH)。
更新日期:2020-04-13
down
wechat
bug